International Journal of Innovative Research and Scientific Studies, 8(6) 2025, pages: 2800-2816

IJIRSS
International Journal of Innovative Research & Scientific Studies

ISSN: 2617-6548

URL: www.ijirss.com

A comprehensive review of nucleic acid-based methods for disease diagnosis, treatment, & prevention

Hessah Mohammed Al-Muzafar

Department of Chemistry, College of Science, Imam Abdulrahman Bin Faisal University (IAU), 31441 Dammam, Saudi Arabia. Basic and Applied Scientific Research Center (BASRC), Imam Abdulrahman Bin Faisal University (IAU), Dammam 31441, Saudi Arabia.

(*Email: hmalmuzafar@iau.edu.sa*)

Abstract

Nucleic acid-based technologies have revolutionized the diagnosis, treatment, and prevention of diseases by enabling highly sensitive and specific detection of genetic material from both pathogens and host cells. These molecular approaches have proven particularly critical in the early detection and surveillance of infectious diseases. For instance, during the outbreak of swine-origin influenza A (H1N1) in Mexico, nucleic acid-based diagnostics were quickly deployed to detect and subtype the virus, and efforts intensified to develop low-cost, point-of-care tests. Such technologies also hold potential for monitoring antiviral resistance mutations and tracking genomic reassortment events with highly pathogenic strains, such as avian influenza. This review provides a comprehensive overview of key nucleic acid amplification techniques—including polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and transcription-mediated amplification (TMA)—with a focus on their principles, advantages, and limitations. Applications across diverse areas such as infectious disease diagnostics, cancer screening, and genetic disorder detection are discussed, with emphasis on tools like circulating tumor DNA (ctDNA), DNA methylation markers, and gene mutation profiling. Furthermore, the therapeutic potential of nucleic acid-based strategies, including gene editing (e.g., CRISPR-Cas systems) and RNA interference, is explored. Finally, the review addresses ongoing challenges, such as sample preparation, assay standardization, and integration into point-of-care platforms, alongside emerging trends that promise to enhance the future of molecular diagnostics.

Keywords: Amplification technologies, Diagnostic methods, Disease surveillance, Infectious diseases, Molecular detection, Nucleic acid, Point-of-care testing.

DOI: 10.53894/ijirss.v8i6.10205
Funding: This study received no specific financial support.
History: Received: 6 August 2025 / **Revised:** 9 September 2025 / **Accepted:** 11 September 2025 / **Published:** 24 September 2025

Competing Interests: The author declares that there are no conflicts of interests regarding the publication of this paper.
Transparency: The author confirms that the manuscript is an honest, accurate, and transparent account of the study; that no vital features of the study have been omitted; and that any discrepancies from the study as planned have been explained. This study followed all ethical practices during writing.
Publisher: Innovative Research Publishing

1. Introduction

The recent SARS epidemic highlighted the profound impact infectious diseases can have on global health, emphasizing the urgent need for rapid and accurate detection methods to control their spread. Traditional diagnostic techniques, such as polymerase chain reaction (PCR), though effective, often require extensive laboratory infrastructure and multiple procedural steps, which can delay timely diagnosis. This challenge has driven significant research into developing simpler, faster, and more precise detection approaches.

Among these, nucleic acid-based diagnostics have emerged as a particularly promising solution. These techniques enable the direct detection of pathogen genetic material, offering rapid, sensitive, and decentralized identification of infectious agents, as well as the ability to detect genetic mutations that may influence treatment strategies. This category encompasses a range of innovative technologies, including microarrays and loop-mediated isothermal amplification (LAMP).

Compared to conventional methods such as culture isolation, immunochemical assays, and even traditional PCR, nucleic acid diagnostics provide critical advantages: they enable quicker detection, higher sensitivity, and valuable epidemiological insights, such as tracking transmission pathways and identifying drug-resistant mutations. A typical nucleic acid diagnostic workflow involves two essential steps: sample pre-treatment and genetic analysis. Pre-treatment, which includes the extraction and purification of target nucleic acids, is crucial for ensuring reliable and consistent results across different testing settings. Optimizing this step is vital because inadequate extraction can lead to under-detection, while excessive processing may degrade nucleic acids. Moreover, stringent measures to prevent contamination are necessary to minimize false positives and enhance diagnostic accuracy. Adherence to established guidelines for contamination control is therefore indispensable in nucleic acid-based testing.

1.1. Background and Significance

Common stains used to enhance microcirculation typically exhibit blue or orange hues, such as crystal violet, gentian violet, azure A, and rhodamine G. Given that (1) a transmission maximum column (SPM) is integrated into the system, and (2) the multispectral camera (MSC) filters out all wavelengths except the transmission wavelength, there is potential to utilize stains beyond the conventional blue or orange spectrum. This enables the observation of micro- and nanoparticles—whose diameters are on the order of the wavelength of light—with optical properties different from typical stains.

Previously, a dual-channel wide-field imaging system combining specialized illumination and microscopy was developed to monitor the uptake of gold nanoparticles (Au NPs) of various sizes into fibroblast cells without causing cellular damage. Building on this, creating a blue wide-field imaging system is critical for observing fibroblast cells stained differently when exposed to colloidal Au NPs around 20 nm in diameter.

To achieve blue channel imaging, a computer-controlled wide-field light microscope was employed, which excited the samples using a narrow-band light source filtered through an excitation filter. The emitted fluorescence passed through an emission filter, allowing clear detection. Transmitted light compatible with blue channel imaging was provided by the SPM, which operates effectively within the 400–480 nm wavelength range, thus enabling bright and high-contrast imaging of the nanoparticles within the cells.

1.2. Scope and Objectives

This review aims to:

(i) summarize the main nucleic acid-based methods currently used for the detection of pathogens causing infectious diseases;

(ii) discuss important considerations related to sample pre-treatment and genetic analysis, especially for novel or emerging techniques;

(iii) provide a brief overview of new nucleic acid-based methods that have potential applications in diagnosis, treatment, and prevention of infectious diseases.

With rapid advances in molecular biology and nucleic acid amplification technologies, these methods offer fast, sensitive, and accurate pathogen detection, including the ability to identify mutations that confer drug resistance. This review focuses on providing a concise summary rather than an exhaustive catalog of all current and emerging technologies [1].

2. Fundamentals of Nucleic Acid-Based Methods

Nucleic acid–based methods have become essential tools in diagnosing infectious diseases, especially in high-impact or life-threatening cases. Used widely in clinical settings, these approaches help not only in disease diagnosis but also in confidently identifying pathogens and conducting genetic analyses. They play a critical role in precision medicine, especially when conventional treatments (e.g., antibiotics or antivirals) are ineffective or delayed. Early detection using nucleic acid methods significantly improves treatment outcomes [2].

Nucleic acids comprise two primary forms: deoxyribonucleic acid (DNA)—the hereditary material of organisms—and ribonucleic acid (RNA), which is essential for protein synthesis based on DNA templates. DNA serves as both the genetic repository and the template for transcription, while RNA plays multiple roles, including serving as a template for protein translation by ribosomes [3]. Both DNA and RNA are composed of nucleotides containing four bases (DNA: adenine, thymine, guanine, cytosine; RNA: adenine, uracil, guanine, cytosine).

For diagnostic use, nucleic acids are first extracted and purified from samples. These raw materials often require amplification—the process of generating many copies of specific DNA or RNA sequences using techniques such as polymerase chain reaction (PCR). There are two broad categories of amplification:

- Isothermal methods, which run at a constant temperature, and
- Thermal cycling methods, which use repeated temperature changes for exponential amplification.

Although amplification adds complexity and cost compared to direct extraction, it enables the sensitive and accurate detection of target sequences.

2.1. Types of Nucleic Acids

The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA carries the genetic instructions used in the growth, development, functioning and reproduction of all known living organisms and many viruses. The instructions are in the form of four types of nitrogenous bases: adenine (A), cytosine (C), guanine (G), thymine (T). An A on one strand always pairs with a T on the second strand, and C always pairs with G. Base pairs are confined to the double helix of DNA and contain the genetic information. Replication of DNA uses one strand of all the unwound helix as a template to make the second strand to form a DNA molecule. This mechanism allows for the precise copying of existing genetic information and constant transmission to most daughter cells [4].

RNA is routinely synthesized on a DNA template by enzymes called RNA polymerases. mRNA carries the information between DNA and the synthesis of proteins. tRNA and rRNA are two basic kinds of RNA that are structural components. In a reverse process to replication, translation of a mRNA uses tRNA to carry genetic information in codons. Each tRNA carries one amino acid from which chains are synthesized into proteins. Base pairs are the key to both replication and translation of DNA [5].

Variants of RNA include a class of small RNAs, and antisense RNA. Non-coding RNAs (ncRNAs) are functional RNAs that are not translated into proteins. RNA exists as a single strand, and unlike DNA which exists only as a double strand with hydroxymethyl groups attached to the 2’ carbon in the ribose, making it more susceptible to hydrolysis. DNA exists as a double strand unless it is in replication or transcription. Each strand of DNA can be used as a template to produce a complementary strand of DNA or mRNA, but RNA does not have a complementary strand. RNA carries the pentose sugars ribose and contains the base uracil (U) instead of thymine (T) [6].

2.2. Principles of Detection

Accurate, fast, and low cost detection strategies are essential for the prevention, diagnosis, and treatment of genetic diseases, viral infections, and microbial pathogens. The primary goal is to design new strategies with sensitivity, easy and fast use, to be useable in different areas such as hospitals, laboratories and in the field [7].

In the last 10 years, there has been significant improvement in new detection strategies for genetic and microbial pathogens. Traditional detection methods like the polymerase chain reaction (PCR), culturing, immune-chromatographic tests, dot blot hybridization, and fluorescence in-situ hybridization, are expensive, laborious, time consuming, and require expensive instruments. Many different applications have been developed as alternatives to traditional methods for the detection of SNPs and genetic mutations. Real-Time PCR is a powerful tool for the detection strategy of genetic and microbial pathogens. There are applications to improve PCR efficiency like the loop-mediated isothermal amplification and isothermal strand displacement reaction. The surface plasmon resonance tool is especially useful in the detection of DNA-DNA, DNA-RNA, and DNA-protein interactions. The microfluidic lab-on-a-chip systems have advanced in the detection of DNA targets. The electronic biosensor can be used in the detection of sequence specific DNA hybridization [8].

The gold standard and most common strategy for the detection of microbial pathogens from biological samples is culturing. Other strategies also used in clinics are antigen-antibody tests and NAATs. The lateral flow biosensor is considered a user friendly and easy-to-use technology for POC diagnostics. In this work a model treating system that enhances the speed of clinical response to not simply detect antibiotic status of patients but also includes: POC nucleic acid-based detection of the bacteria, the availability of flexible resistors, and the diffusion of genes. All these applications are useful for the detection of microbial pathogens like Mycobacterium tuberculosis, Staphylococcus aureus, Chlamydia trachomatis, Neissera gonorrhoeae, and Streptococcus pyogenes [9].

3. Applications in Disease Diagnosis

Nucleic acid-based methods have gained significant attention since the discovery of PCR [1]. These methods target specific genetic sequences, making them valuable alternatives to protein-based diagnostics like antibodies or antigens. Major classes include aptamers, antisense oligonucleotides (e.g., siRNA, shRNA, miRNA), and triplex-forming oligonucleotides (TFO).

3.1. Infectious Diseases

Infectious diseases, mainly caused by bacteria, viruses, fungi, and parasites, remain a major global health concern, causing over 13 million deaths annually, mostly in developing countries [1]. Traditional diagnostics such as culture and serological tests are often slow and may suffer from loss of sample viability during transport. In contrast, nucleic acid-based diagnostics (NABDs) enable rapid, sensitive, and specific detection by targeting unique pathogen genetic material. Early and accurate diagnosis is critical for timely treatment and controlling disease spread, especially with the rise of antimicrobial resistance (AMR), which has been accelerated by the misuse of antibiotics [10].

3.2. Cancer

Early detection of cancer is essential for improving patient outcomes. Nucleic acid-based methods focusing on cell-free DNA (cfDNA) and DNA methylation have emerged as promising diagnostic tools. DNA methylation, an epigenetic modification involving the addition of methyl groups to cytosines, affects gene expression and differs between cancerous and healthy cells [11]. Detecting these methylation patterns can aid early cancer diagnosis, although traditional methods are often expensive and time-consuming. Recent approaches aim to quantify DNA methylation quickly and cost-effectively without detailed genome mapping, using cfDNA from blood samples as a non-invasive biomarker [12, 13]. While histone modification is an important epigenetic marker, its direct use in diagnostics is still under development and less established compared to DNA methylation.

3.3. Genetic Disorders

Analysis of the DNA has led to early diagnosis of a range of medical conditions, including genetic disorders, malignancies, and infectious diseases – Children with non-specific clinical abnormalities, who often fit into categories of multiple genetic problems, can be accrued in whom it is difficult to correct a definitive diagnosis. Any change in the sequence of the DNA can be pathologic if it has an abnormal effect on the biologic pathways within the cell and/or its environment, disrupting the normal function. Because mitochondria are assumed to originate from ancestral organized structures in a diverse manner from the nuclear DNA, mutations can curb the structure of a host of mitochondrial proteins. The salient protection about mitochondrial mutations is that pathologic DNA prominences would depend on the nature of the mutation and the percent of mitochondrial mutant species. Characterization of the genetic basis of the disease is necessary for an accurate diagnosis. With the accretions of pedigree details the clinician is often reminded of a specific genetic problem and surfaces that there may be an accumulation of these problems in patients [14].

PCR can amplify very negligible amounts of DNA. Since its introduction, PCR has been refreshed and adapted to enormous accommodated applications. The technique has been habituated for the diagnosis of a plethora of inherited diseases on the DNA level. There are several facets in PCR established tests that should be addressed. DNA contamination should be avoided, as it may cause a false positive result. With modern techniques no amplicon can be happily postulated to be generated from a single DNA molecule. In DNase- and RNase- free bootees, there is sterility from amplification of the negative control in the absence of DNA. Since PCR would amply examine the DNA present in contaminated salve, great caution should be allotted when working with PCR to escape false positive results [15].

4. Therapeutic Applications

Nucleic acids possess extraordinary potential to distinguish cells at the level of DNA and RNA sequences. The four biochemical set-up blocks in the sequence of base-pairs that constitute DNA and RNA give them an exceptionally far-reaching range of possible molecular compositions in comparison to the 20 constituent amino acids for proteins. With the rapidly decreasing costs for both gene synthesis and the entire sequencing of DNA and RNA, nucleic acids are becoming an increasing competitive platform for the design of molecules possessing high phylogenetic selectivity. Unrestricted target choice in turn places nucleic acid aptamers and synthetic oligonucleotides for antisense, RNA interference, and gene editing technologies in the advantageous position of addressing undruggable proteins. With the issues of delivery and specificity steadily providing solutions, range of disease types that are conceivable to tackle with spatio-temporally customized protein recognition reagents seems not to have an explanatory cellar. Given the challenges in target validation and the robustness seen in other biomolecule therapeutics, such as antibodies, the thoughtful investigation and advancement of the limits of nucleic acid-based strategies over the next decade promises large rewards [16].

Nucleic acids have various potential applications in medicine, including diagnostics, therapy, and prophylaxis. Nucleic acids can interact specifically with molecular targets due to base-pairing, which makes them a powerful tool for design of artificial compounds recognizing given markers. In the evolutionary arms race between pathogens and host organisms, the possibility to rapidly vary the biochemical nature of immune responses by changing the genetic sequence of antibodies detected the pathogen is a powerful weapon from the vantage of organisms advanced with an adaptive immune system. Moreover, in vitro selection methods allow for the evolution of nucleic acid molecules with high affinity and specificity for virtually any molecular target, which makes them a very stable and valuable alternative to protein recognition reagents. As a result, in the last decades, a number of nucleic-acid-based molecules have been created (aptamers, ribozymes, anti-sense oligonucleotides and others), which are currently under consideration for various biomedical applications, including the development of novel approaches for the treatment and prophylaxis of infectious diseases [17].

4.1. Gene Therapy

In the past few decades, a variety of therapeutics options based on the nucleic acid technologies have introduced into clinical management of several diseases. Researchers have had a great deal progress and some of them have already had a significant impact on the diagnosis, treatment and prevention of diseases. Gene therapy (GT) is a powerful technique that directly modifies the genes of a person. GT involves either replacing a mutated gene with a healthy one, repairing a mutated gene, or adding a new gene. Furthermore, gene editing (GE) is a simple innovation in the ongoing development of the GT, which involves making precise modifications in a DNA sequence. Four mainly used GE techniques mentioned here, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALEN), CRISPR-associated protein 9 nuclease (CRISPR/Cas9) and Oligonucleotide (ON). The successful Vance GE and subsequent techniques have revolutionized the ability of science to undertake genetic editing, and therefore generated excitement about the potential applications in a variety of fields. While they offer great opportunities for study and pose the possibility to offer great

therapeutic benefit, an unintended effect of these technologies could have unforeseen consequences that could impact humanity's health. Many scientists, ethicists and business have already politically petitioned and successfully banned the use of CRISPR-Cas9 on human embryos [18]. Scientists have successfully altered human DNA in embryos for the first time in the US, according to a report [19].

4.2. Antisense Oligonucleotides

Oligonucleotides are short sequences of RNA or DNA usually 20–25 bases in length that have demonstrated properties suitable for therapeutic development [20]. There are different types of oligonucleotides used in therapeutic applications, the classical antisense oligonucleotides that inhibit gene expression through catalytic action of ribonuclease H, the steric blocker antisense-type which hinders translation by preventing interaction between mRNA and ribosomes. In addition, there are relatively newer forms of oligonucleotides like siRNAs, miRNAs, and other single-stranded RNAi triggers that directly induce RNA interference in a catalytic fashion. Antisense oligonucleotides are some of the most widely developed gene-targeting therapeutics. They can be synthesized with chemical modifications that increase nuclease resistance, reduce immune activation, and increase cellular uptake. They can interact with diverse cellular proteins, can be designed to target RNAs with extraordinary sequence selectivity, and they have been found to have potent, dose-dependent, predictable, on-target activity in animals when administered systemically. Despite high hopes, and over 30 years of study, the development of oligonucleotide-based therapeutics has been marred by analytical difficulties and an incomplete understanding of their biological effects across functional genomics. RNA is a much more complex molecule than originally appreciated, the RNA world is now known to be a gene-expression control center of immense complexity and diversity. While transcriptional regulatory networks are extraordinarily complex, human transcript numbers and the number of observed non-coding transcripts are in fact close to those predicted by the simplest models of random transcription and assembly. Much less work has been done on the protein/ASO and protein/single-stranded DNA interaction landscape. Understanding these aspects of oligonucleotides may better enable technological advances and the development of more potent, less toxic therapeutics [21].

5. Challenges and Future Directions

In the past two centuries, immense technological advancements have been made in the life sciences, bringing about the development of countless diagnosis and treatment skills for an equivalent number of diseases. Yet many modern diseases that humankind suffers from today can only be traced back to the previous century. Medical science, as advanced as it is, constantly faces new challenges. To tackle those, researchers have been making endless efforts and discoveries in related fields. DNA nanotechnology is a variety of nanotechnology that works at the nanometer scale of DNA. The discipline of DNA nanotechnology has evolved significantly over the last three decades, during which the size of nanotechnology has decreased gradually. Nowadays, DNA nanotechnology is a highly interdisciplinary field, combining methods from physics, bioinformatics, DNA origami, and multidisciplinary approaches to chemistry, bioengineering, and molecular therapeutics [22]. Although there has been great progress in the diagnosis and treatment of various diseases within the last two centuries, there are still some issues that are particularly challenges for current medical diagnosis. Firstly, there are always new diseases appearing and the mechanism of previously known diseases is not adequately understood; secondly, misdiagnosis has a high incidence rate and it is quite difficult to cure many kinds of diseases; third, recent years have seen the burgeoning rise of drug resistance in various strains of diseases, therefore, meaning that even global public health policies are under extensive threat. Previously, to detect and diagnose diseases, people have remained very dependent on symptom-related approaches. As a general procedure, doctors enquire about general symptoms from a patient and either conclude the type of disease from their own experience or give specific directions to go to a special laboratory to take diagnostic tests based on the most relevant symptoms. Nowadays, the standard methods of diagnosis are clinical tests, X-rays, ultrasonic tomography, computed tomography (CT), endoscopy, magnetic resonance imaging, angiography, blood tests, and so forth, which depend on the disease in question. But only making such a diagnosis by examining the relevant symptoms or performing these tests has proved over time to be extremely error-prone. The reasons for this include the huge variety of modern diseases, similarities in their symptoms, and that some diseases proceed asymptomatically in the beginning. Moreover, some infections may be dormant or the body might not have developed enough error symptoms in the dormant stage. That means mistakes may flood in during or shortly after the examination and diagnosis. A previously non-randomized treatment based on a little knowledge database of general symptoms may not work effectively. Mistakenly prescribed medicines could cause sundry chronic side-effects or indirectly prepare the ground for new kinds of diseases, this, in some sense, is a more pernicious situation and might imperatively end in death, the blackment of a number of afflictions is certain, such as the copious number of infections developing drug resistance, autoimmune diseases and cancers due to chronic pollution. Hence, an urgent need for an adjunctive emulative but also revolutionary alternative methodology in a dire need of medical diagnosis. This vital need pushes on some researchers to introduce new bio-medical science and technological platforms to campaign against the old and prevalent methodology to detect these types of critical diseases. They conspectus the recognition of this technology is looking intolerably vigorous, significantly unexpected future fructification, as well as a fundamental element in the solution for the signify its vitality and prefigurability. The decision paradigm in biomedicine will be discussed to cope with improving in standards with increasing the perception to produce and analyze more significant results to increase the competition at the undergraduate stage and to the granulate new and selective choice of these and do with the phthalides from early knowledge of different stages of higher studies. This paradigm is thought to last with a unique and indispensable role integrating methodologies, depending on from the traditional medical and basic sciences to physics, chemistry, biology and such more. Such a framework demands the

development of certain modern and sophisticated platforms encompassing protocols and measures to guide the maintenance of a closer and more meaningful collaboration among investigators from different disciplines. This need towards the realization of new bio-medical science and technological platforms to play an increasingly appreciated and significant role in the efforts to fundamentally understand and diagnose diseases in life genetic and cellular levels. At such scales, technology has already been put to striking use to probe the physical properties of substances and infestations setting studies, inventing uses of materials, and informing physical spent animals to life begins functioning. Powerful means of researching the subject threaten to intersect the growing share of unknown before genetic information in genome and the treatment of numerous deleterious the visual means of diseases are thought required to proffer true personalized therapeutic strategies at a scale. A little hope is now only for these developers to embrace the exciting and fast-moving field of bionanotechnology [23, 24].

5.1. Ethical Considerations

There are few main ethical considerations surrounding the preferential use of nucleic acid-based methods, such as PCR and LAMP. Commonly recognized tendencies are related to social determinants, person-centered precautions which might lead to stigmatization of socially vulnerable groups. In genetic diagnostics, the examined person and his/her biological relatives become objects of study. It increases the risk of disclosure of unauthorized information. With nucleic acid-based diagnostics, sequencing techniques may be used that may result in secondary findings beyond the diagnostic question asked. Finally, health care personnel has reported an unfulfilled need to discuss with a patient the need for genetic testing and the implications of the genetic results [7].

5.2. Technological Advancements

1. Recent Advancements in Nucleic Acid-Based Methods for the Diagnosis of Gastrointestinal Tract Infections Various organisms such as viruses, bacteria, protozoans, and helminthes have been shown to infect the gastrointestinal tract resulting in disease. Classical microbiological techniques have been routinely used for detecting such agents. The advent of molecular methods has allowed for the identification of organisms that in many cases cannot be cultured, such as Norovirus and Arcobacter spp. It also allows for higher throughput and faster turnaround. Considering the local burden of illness due to various gastrointestinal pathogens, efforts should be made to improve and expand such methods [25].

2. Recent Techniques and Technological Advancements in Nucleic Acid-Based Therapeutics for the Potential Treatment of Inherited Disease Many mutations in the genome are linked to a wide range of genetic disorders. The genes related to these diseases are made up of various lengths of DNA and RNA strands. The recent development of gene-editing technologies is notable since they can target a specific DNA sequence, for example a deleterious mutation, and modify it. Similar RNA-protein complexes have been found and can be brought into cells with nucleic acids. They can also bind to specific mRNAs and direct them to be destroyed. This has potential in therapeutics. With recent advancements in nucleic acid delivery vectors, nucleic acid-based therapeutics have the meaningful potential to become a powerful and precise therapeutic modality for a wide range of conditions. The review will discuss a number of recent techniques developed for such purpose [26].

6. Questionnaire, Analysis, Discussion, and Conclusion

Nucleic acid amplification technology has revolutionized the detection of infectious agents and diseases. Experimental design has been optimized for highly sensitive and specific amplification procedures. A broad range of infectious agents and diseases have been successfully targeted by several PCR instruments, innovative chemistries, and detection systems. Multiplex reaction procedures have been created for amplification detections. New tests for tick- and mosquito-borne pathogens are presented. The relative advantages of commonly used nucleic acid amplification procedures for diagnostic testing is discussed. Detecting West Nile virus in formalin-fixed, paraffin-embedded human tissues by reverse transcriptase polymerase chain reaction amplification and nonisotopically labeled hybridization techniques. This approach provides an excellent adjunct to conventional tissue-based diagnostic testing procedures. It is especially useful when acute-phase clinical specimens are no longer available. Causes and implications of false-positive results and contamination encountered in routine laboratory application of PCR amplification technology is also reviewed. Methods useful for preventing these events are presented. RTPCR technology is sufficiently sensitive that even limited contamination can yield false-positive signals. Clinicians and pathologists should be aware of the possibility of type I (contamination) and type II (incorrect specimen handling or mix-up) errors when interpreting RTPCR and DNA amplification results. Used correctly, these techniques have considerable potential to improve patient care. Early diagnosis and treatment of infectious agents is critical when dealing with life-threatening infections, the arguments for the appropriate use of antimicrobial agents and the possible use of molecular diagnostics in life-threatening infections is reviewed. Patients fortunate enough to have a bacterium ... has also reported their contention that rapid therapeutic intervention saved lives, limb, or brain function in patients with bacteremia caused by gram-negative bacilli, in a murine model of sepsis, the importance of prompt initiation and appropriate duration of antimicrobial therapy on survival was directly demonstrated. Detection of extracellular, even partially lysed gram-negative bacilli in the blood stream was decreased from 5 to 10 min, with more extensive lethality after 15 min of antibiotic treatment. Similarly, members of the Polish sepsis group also reported that for septic patients, empiric antibiotic therapy begun after the start of shock was associated with increased mortality. Areas of the Italian Study Group on Severe Infections in Intensive Care Units has also recently advocated the aggressive use of broad spectrum antimicrobials against nosocomial strains of gram-negative bacilli detected in blood pathogens, even if this practice involves the use of two drugs since the beginning of therapy. Considering the rampant increase in drug resistance observed

among gram-negative bacilli in the last decade, these patients may benefit from the early use of antimicrobials. The purpose of this review is to emphasize the idea that antimicrobial therapy for life-threatening infections must be treated as a medical emergency, taking into account the golden hour concept described by others. Methodologically different approaches, often initiated simultaneously: genetic assays of body fluids with serologic testing on the corresponding biopsies and serologic assay of early acute-phase biopsy fluids with PCR performed on acute-phase plasma would have led promptly to the diagnosis. Close correlation of pathologic features with the first detection by PCR assay of a viral pathogen in tissue biopsies should have suggested the application of modified serologic and PCR testing in the same tissue post-crush smears in a lymph node or similar tissue. Finally, molecular confirmation of the index PCR finding in a separate tissue should ... Nucleic acid amplification techniques, specifically the nucleic acid hybridization protection assay, have revolutionized the detection of hepatitis C virus infection and have permitted the accurate quantitation of viremia. Quantitative viremia testing was performed on more than 1,000 anti-hepatitis C antibody-negative, HCV RNA-positive blood donors, asymptomatic orthopedic patients, HCV-transfused thalassemic patients, and blood recipients of anti-HCV positive units. Accuracy was verified by the use of serial dilutions of tested HCV genotypes. Active replication was transferred in anti-HCV-negative blood donors, HCV-positive transfused patients, and blood recipients of anti-HCV-positive units, genotypes being especially detected. Post-transfusion HCV positivity imparted valuable information regarding vaccination prevalence in donors and potential vaccine effectiveness. Discontinuation of testing is suggested for the latter diseases and their associated antibodies prior to molecular diagnosis. Detection of hepatitis C virus RNA by nucleic acid amplification testing technology currently assumes an important position in the laboratory diagnosis of HCV infection. Such testing has the potential to identify more early acute-phase anti-HCV-positive patients and to distinguish false-positive and biologically insignificant reactions from truly infected individuals. The success of amplification in commercial assays largely depends on the ability to detect and prevent misevaluation and/or misinterpretation of false-positive results. Procedures can be highly susceptible to exogenous contamination, which may result in false signals in a controlled lab background. A problem in clinical workplaces is that they are not so stringently controlled, so that the actual contamination may happen unseen. To determine the extent of extraneous amplification product carryover contamination in a lab whose samples are routinely amplified, disposable barriers were placed into the course of the labware resulting in improved conditions for preparation. The accumulated experience of controlling the contamination yielded zero false-positive results in years of PCR testing run. The prevention and near absolute elimination of the extraneous product contamination are very labor- and money-consuming. Rapid detection of bacterial, viral, and fungal pathogens in septic patients is of utmost importance to promptly establish an adequate or specific antimicrobial therapy. Until recently, the reliability and rapidity of traditional culture-based methods were considered sub-optimal due to their low yield in identifying the etiological agents in a rapid timeframe. The isolation of a given microbial pathogen using standard blood cultures may take between days and weeks, depending on the microorganism involved and the culture techniques employed. Thus, conventional microbiological tests have become less and less useful, particularly in high-risk patient populations such as those with underlying immunosuppression or in patients in intensive care units where multiple comorbid conditions may mask the septic condition. Over the past decade, there has been an extensive effort to develop new technologies which, either alone or in combination with classical methods, may improve the detection of pathogens. Among the many technical advances, great expectations have been placed on polymerase chain reaction-based methods. PCR has the capability to amplify nucleic acid targets with an exponential growth in a short time by using a pair of primers that hybridize to specific regions of the target, the enzyme polymerase that extends the annealed primers, thus generating a complementary copy of the DNA template, and deoxyribonucleoside triphosphates as precursors for the newly synthesized strand. PCR is one of the most common amplification reactions used in molecular diagnostics due to its sensitivity. As few as 3-5 copies of a given DNA sequence can theoretically be detected in a DNA sample by using this technique. However, the possibility to detect sequences at levels lower than the theoretical limit is hampered by a number of factors, including the potential for minute contamination of reagents and amplicon of the previous reaction setup, as well as interference from the presence of nontarget DNA [1].

Table 1.
Questionnaire.

Review Article: A Comprehensive Review of Nucleic Acid-Based Methods for Disease Diagnosis, Treatment, & Prevention							
No.	Circle the correct numeric response to the following Questionnaire	Survey Scale: 1=Strongly Disagree 2=Disagree 3=Neutral 4=Agree 5=Strongly Agree					
Age							
Academic Education (Bachelor, Master, PhD)							
Job							
Position (Employee, Manager)							
1	Nucleic acid-based diagnostics provide rapid, precise, and sensitive identification and diagnosis of microorganisms responsible for infectious illnesses.	1	2	3	4	5	
2	Nucleic acid amplification technologies (NATs) have transformed the identification of infectious agents and illnesses.	1	2	3	4	5	
3	Isothermal techniques, including transcription-mediated amplification (TMA) and loop-mediated nucleic acid amplification (LAMP), are very appropriate for creating novel assays to address pandemic influenza.	1	2	3	4	5	
4	The use of nucleic acid-based diagnostics may significantly decrease the time needed for the detection of infectious disorders.	1	2	3	4	5	
5	Nucleic acid amplification methods, including PCR, have enhanced the identification of infections in septic patients.	1	2	3	4	5	
6	Nucleic acid-based diagnostics may improve patient outcomes by facilitating early detection and treatment of infectious disorders.	1	2	3	4	5	
7	In the early acute phase, nucleic acid amplification technologies (NATs) have the potential to effectively identify a greater number of patients who are anti-HCV-positive and to distinguish between genuine infected individuals and false-positive or physiologically inconsequential responses.	1	2	3	4	5	
8	The precision of nucleic acid amplification testing is contingent upon the avoidance and near-total eradication of extraneous product contamination.	1	2	3	4	5	
9	Diagnostics based on nucleic acids are absolutely needed for tracking the evolution of antiviral drug resistance mutations and likely reassortment of gene segments with highly pathogenic avian influenza viruses.	1	2	3	4	5	
10	The field of infectious disease diagnosis, treatment, and prevention may undergo a radical change with the advent of nucleic acid based diagnostics.	1	2	3	4	5	

Table 2.
Questionnaire' Results.

Review Article: A Comprehensive Review of Nucleic Acid-Based Methods for Disease Diagnosis, Treatment, & Prevention										
	Q_1	**Q_2**	**Q_3**	**Q_4**	**Q_5**	**Q_6**	**Q_7**	**Q_8**	**Q_9**	**Q_10**
MEAN	3.787	3.733	3.827	3.987	3.907	3.827	3.653	3.893	3.720	3.787
MODE	4.000	4.000	4.000	4.000	4.000	4.000	3.000	4.000	4.000	4.000
StDev	0.800	0.900	0.900	0.800	0.800	0.900	1.000	0.800	0.900	0.900
StErr	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100	0.100
F	0.508	0.268	0.809	0.337	0.316	0.231	0.005	0.317	0.594	0.462
TTEST	0.773	0.061	0.008	0.198	1.000	0.154	0.803	0.073	0.000	0.002

Table 3.
Questionnaire's Respondents.

Review Article: A Comprehensive Review of Nucleic Acid-Based Methods for Disease Diagnosis, Treatment, & Prevention													
No.	**Respondent Type**	**Q_1**	**Q_2**	**Q_3**	**Q_4**	**Q_5**	**Q_6**	**Q_7**	**Q_8**	**Q_9**	**Q_10**	**Sum Q1 to 10**	**Rank Q1 to 10**
1	Head of Section	4	3	4	5	3	4	3	5	3	4	38	40
2	Head of Section	3	3	3	5	4	5	3	4	3	5	38	40
3	Head of Section	4	3	3	3	4	4	4	3	5	4	37	52
4	Head of Section	5	3	4	5	4	3	3	3	5	4	39	29
5	Head of Section	3	3	4	5	5	4	3	4	4	4	39	29
6	Head of Section	5	3	3	3	3	5	4	3	4	3	36	59
7	Head of Section	4	3	3	5	4	4	3	5	5	4	40	21
8	Head of Section	4	4	4	4	3	3	3	4	4	4	37	52
9	Head of Section	4	4	5	4	3	5	3	3	4	3	38	40
10	Head of Section	3	3	4	4	3	4	3	3	3	4	34	71
11	Head of Section	4	3	3	5	4	3	3	4	4	3	36	59
12	Head of Section	3	5	4	5	4	3	5	4	4	3	40	21
13	Head of Section	3	4	4	4	3	5	3	4	3	5	38	40
14	Head of Section	4	3	4	4	4	5	4	5	3	3	39	29
15	Head of Section	4	3	3	3	3	4	5	3	3	4	35	63
16	Expert	3	3	3	3	3	4	5	3	3	3	33	77
17	Expert	4	3	3	4	4	4	4	4	4	4	38	40
18	Expert	4	4	5	2	3	3	2	2	5	4	34	71
19	Expert	3	3	4	2	5	4	3	3	2	5	34	71
20	Expert	4	4	4	5	3	5	4	4	4	4	41	15
21	Expert	5	2	5	4	4	3	4	5	5	2	39	29
22	Expert	3	5	2	4	5	3	2	3	2	4	33	77
23	Expert	4	2	4	4	2	2	4	4	4	2	32	87
24	Expert	4	3	4	4	4	5	5	2	4	2	37	52
25	Expert	2	5	4	4	4	3	3	3	2	4	34	71

26	Expert	4	4	4	4	3	4	3	3	3	4	36	59
27	Expert	4	4	5	3	4	3	3	5	4	3	38	40
28	Expert	3	5	5	3	5	3	4	4	5	4	41	15
29	Expert	3	3	4	4	4	4	3	4	4	3	36	59
30	Expert	4	3	4	5	5	5	4	4	4	4	42	9
31	Expert	4	5	3	4	4	4	4	5	4	4	41	15
32	Expert	4	4	5	4	4	5	3	5	4	4	42	9
33	Expert	5	4	4	4	4	5	4	3	5	4	42	9
34	Expert	4	5	5	4	5	4	4	4	4	4	43	5
35	Expert	5	3	4	5	5	4	4	3	5	3	41	15
36	Expert	3	3	4	4	3	4	4	5	4	4	38	40
37	Expert	4	3	4	5	4	4	4	5	4	4	41	15
38	Expert	4	5	4	4	4	4	5	3	3	4	40	21
39	Expert	4	4	5	3	4	4	3	5	3	5	40	21
40	Expert	5	5	4	3	4	3	4	3	4	4	39	29
41	Expert	4	4	5	4	5	3	3	3	4	4	39	29
42	Expert	4	5	4	4	3	4	4	4	4	3	39	29
43	Expert	4	5	5	4	4	4	4	4	4	5	43	5
44	Expert	4	4	4	4	4	4	5	3	3	4	39	29
45	Expert	3	3	4	4	5	4	4	3	4	4	38	40
46	Expert	4	4	4	3	5	5	3	3	4	4	39	29
47	Expert	4	4	3	4	5	5	5	4	5	4	43	5
48	Expert	3	5	4	5	3	3	4	3	4	3	37	52
49	Expert	3	4	3	4	4	5	4	4	3	5	39	29
50	Expert	5	5	3	5	4	4	3	5	3	5	42	9
51	Expert	4	4	5	4	3	5	5	5	4	3	42	9
52	Expert	4	3	3	3	5	5	3	4	5	5	40	21
53	Expert	4	3	3	4	4	4	5	5	3	5	40	21
54	Expert	4	4	5	3	5	3	4	4	4	4	40	21

55	Expert	4	4	4	4	4	3	3	5	5	5	41	15
56	Expert	5	3	5	5	4	4	5	5	4	5	45	1
57	Expert	5	4	4	5	4	3	5	5	5	4	44	3
58	Expert	3	5	4	4	3	4	3	4	3	5	38	40
59	Expert	4	4	5	5	5	3	5	4	4	5	44	3
60	Expert	5	4	5	5	5	3	3	4	4	4	42	9
61	Expert	5	4	3	5	5	4	5	5	4	5	45	1
62	Expert	5	3	5	5	5	4	5	4	4	3	43	5
63	Expert	3	5	1	5	3	5	1	5	1	3	32	87
64	Expert	3	5	3	3	5	3	5	5	3	5	40	21
65	Expert	3	1	5	5	3	5	1	5	5	5	38	40
66	Expert	5	5	3	3	5	1	5	5	3	3	38	40
67	Expert	4	3	3	4	3	4	3	3	3	3	33	77
68	Expert	1	4	3	4	3	3	1	4	1	3	27	99
69	Expert	3	4	3	3	4	4	3	4	4	1	33	77
70	Expert	4	4	1	4	3	4	4	3	3	3	33	77
71	Expert	4	2	4	4	4	3	3	3	2	2	31	95
72	Expert	4	4	4	2	3	2	2	4	4	3	32	87
73	Expert	2	4	4	4	2	2	4	4	4	4	34	71
74	Expert	2	4	4	2	4	4	4	3	3	2	32	87
75	Expert	3	3	2	4	4	4	4	3	4	4	35	63
76	Expert	4	4	4	3	4	4	3	3	4	4	37	52
77	Expert	4	4	3	4	4	4	4	4	4	4	39	29
78	Expert	3	4	4	4	3	3	4	3	4	3	35	63
79	Expert	3	4	3	4	4	4	4	4	3	4	37	52
80	Expert	4	4	3	4	4	4	3	4	3	4	37	52
81	Expert	4	4	4	4	3	4	4	4	4	3	38	40
82	Expert	4	3	3	3	4	4	3	2	4	4	34	71
83	Expert	4	3	3	2	2	4	4	4	3	4	33	77

84	Expert	2	2	4	3	4	3	4	2	2	2	28	97
85	Expert	4	2	4	2	2	3	3	4	4	4	32	87
86	Expert	4	3	4	4	2	2	4	4	4	4	35	63
87	Expert	4	4	4	4	2	3	4	4	4	2	35	63
88	Expert	3	4	2	4	3	2	3	4	3	4	32	87
89	Expert	4	2	4	4	4	3	4	2	4	4	35	63
90	Expert	4	2	4	4	4	3	3	2	2	2	30	96
91	Expert	4	2	3	4	4	2	4	4	4	4	35	63
92	Expert	4	3	4	4	4	2	4	2	2	3	32	87
93	Expert	3	4	1	4	3	4	1	4	1	3	28	97
94	Expert	3	4	3	3	4	3	4	4	3	4	35	63
95	Expert	3	1	4	4	3	4	1	4	4	4	32	87
96	Expert	4	4	3	3	4	1	4	4	3	3	33	77
97	Expert	4	3	3	4	3	4	3	3	3	3	33	77
98	Expert	1	4	3	4	3	3	1	4	1	3	27	99
99	Expert	3	4	3	3	4	4	3	4	4	1	33	77
100	Expert	4	4	1	4	3	4	4	3	3	3	33	77

Review Article: A Comprehensive Review of Nucleic Acid-Based Methods for Disease Diagnosis, Treatment, & Prevention

Survey Scale: 1=Strongly Disagree 2=Disagree 3=Neutral 4=Agree 5=Strongly Agree

Question	# 1's	#2's	#3's	#4's	#5's	n	MEAN	MODE	SEM
1. Nucleic acid-based diagnostics provide rapid, precise, and sensitive identification and diagnosis of microorganisms responsible for infectious illnesses.	2	4	27	54	13	100	3.79	4	***0.1***
2. Nucleic acid amplification technologies (NATs) have transformed the identification of infectious agents and illnesses.	2	8	32	42	16	100	3.73	4	***0.1***

3. Isothermal techniques, including transcription-mediated amplification (TMA) and loop-mediated nucleic acid amplification (LAMP), are very appropriate for creating novel assays to address pandemic influenza.	4	3	31	45	17	100	3.83	4	***0.1***
4. The use of nucleic acid-based diagnostics may significantly decrease the time needed for the detection of infectious disorders.		6	20	53	21	100	3.99	4	***0.1***
5. Nucleic acid amplification methods, including PCR, have enhanced the identification of infections in septic patients.		6	30	45	19	100	3.91	4	***0.1***
6. Nucleic acid-based diagnostics may improve patient outcomes by facilitating early detection and treatment of infectious disorders.	2	7	29	45	17	100	3.83	4	***0.1***
7. In the early acute phase, nucleic acid amplification technologies (NATs) have the potential to effectively identify a greater number of patients who are anti-HCV-positive and to distinguish between genuine infected individuals and false-positive or physiologically inconsequential responses.	6	3	35	40	16	100	3.65	3	***0.1***
8. The precision of nucleic acid amplification testing is contingent upon the avoidance		7	29	43	21	100	3.89	4	***0.1***

and near-total eradication of extraneous product contamination.									
9. Diagnostics based on nucleic acids are absolutely needed for tracking the evolution of antiviral drug resistance mutations and likely reassortment of gene segments with highly pathogenic avian influenza viruses.	4	7	28	48	13	100	3.72	4	***0.1***
10. The field of infectious disease diagnosis, treatment, and prevention may undergo a radical change with the advent of nucleic acid based diagnostics.	2	8	27	47	16	100	3.79	4	***0.1***

The survey results indicate a high level of agreement among experts on the effectiveness and potential of nucleic acid-based diagnostics for disease diagnosis, treatment, and prevention, the mean scores for all questions range from 3.65 to 3.99, indicating a strong consensus among experts, the results suggest that experts believe nucleic acid-based diagnostics provide rapid, precise, and sensitive identification and diagnosis of microorganisms responsible for infectious illnesses (Q1), they also agree that nucleic acid amplification technologies (NATs) have transformed the identification of infectious agents and illnesses (Q2), the experts strongly agree that isothermal techniques, such as transcription-mediated amplification (TMA) and loop-mediated nucleic acid amplification (LAMP), are well-suited for developing new assays to combat pandemic influenza (Q3), they also believe that the use of nucleic acid-based diagnostics can significantly decrease the time needed for the detection of infectious disorders (Q4), the results indicate that experts agree that nucleic acid amplification methods, including PCR, have enhanced the identification of infections in septic patients (Q5), they also believe that nucleic acid-based diagnostics can improve patient outcomes by facilitating early detection and treatment of infectious disorders (Q6).

Recommendations include the need for further research to fully explore the potential of nucleic acid-based diagnostics for disease diagnosis, treatment, and prevention; development of new tests using isothermal techniques, such as TMA and LAMP, to combat pandemic influenza; implementation of nucleic acid-based diagnostics in clinical settings to reduce the time to detect infectious disorders; training and education of healthcare professionals on the use and interpretation of nucleic acid-based diagnostics; standardisation of nucleic acid-based diagnostics to ensure accuracy and reliability across different laboratories and settings; and ongoing monitoring and evaluation of the effectiveness and potential of nucleic acid-based diagnostics in real-world settings. Number of experts in the survey: It is possible that the survey sample size of one hundred experts does not accurately reflect the wider community of experts in the subject; Design of the survey: It is possible that the survey design did not take into account all of the pertinent components of diagnostics based on nucleic acids; also, Due to the fact that experts may have been more inclined to reply to the survey if they had strong views on the issue, their replies may be prone to bias. The research has several limitations, as stated above.

Future Research Directions include comparative studies, comparative studies of different nucleic acid-based diagnostics to determine their relative effectiveness and potential, cost-effectiveness analysis, cost-effectiveness analysis of nucleic acid-based diagnostics to determine their potential impact on healthcare systems, and real-world implementation studies: real-world implementation studies of nucleic acid-based diagnostics to determine their effectiveness and potential in clinical settings.



Figure 1.
Questionnaire's Analysis.



Figure 2.
Questionnaire's Analysis

References

[1] Y. A. Cheung-Hoi *et al.*, "Nucleic acid-based diagnostics for infectious diseases in public health affairs," *Frontiers of Medicine*, vol. 6, no. 2, pp. 173-186, 2012. https://doi.org/10.1007/s11684-012-0195-5

[2] C. W. Stratton and Y.-W. Tang, "Interpretation and relevance of advanced technique results." Cham: Springer, 2018, pp. 711-740.

[3] Y. Wang *et al.*, "Advances in simple, rapid, and contamination-free instantaneous nucleic acid devices for pathogen detection," *Biosensors*, vol. 13, no. 7, p. 732, 2023. https://doi.org/10.3390/bios13070732

[4] B. R. Glick and C. L. Patten, *Molecular biotechnology: Principles and applications of recombinant DNA*. Hoboken, NJ: John Wiley & Sons, 2022.

[5] E. Kummer and N. Ban, "Mechanisms and regulation of protein synthesis in mitochondria," *Nature Reviews Molecular Cell Biology*, vol. 22, no. 5, pp. 307-325, 2021. https://doi.org/10.1038/s41580-021-00332-2

[6] N. G. Walter, "Are non-protein coding RNAs junk or treasure? An attempt to explain and reconcile opposing viewpoints of whether the human genome is mostly transcribed into non-functional or functional RNAs," *BioEssays*, vol. 46, no. 4, p. 2300201, 2024. https://doi.org/10.1002/bies.202300201

[7] M. Baloda, "Lateral flow nucleic acid biosensor for the detection of sexually transmitted diseases," Doctoral Dissertation North Dakota State University, 2015.

[8] N. Li, Q. Cai, Q. Miao, Z. Song, Y. Fang, and B. Hu, "High-throughput metagenomics for identification of pathogens in the clinical settings," *Small Methods*, vol. 5, no. 1, p. 2000792, 2021. https://doi.org/10.1002/smtd.202000792

[9] R. Xu, N. Deebel, R. Casals, R. Dutta, and M. Mirzazadeh, "A new gold rush: a review of current and developing diagnostic tools for urinary tract infections," *Diagnostics*, vol. 11, no. 3, p. 479, 2021. https://doi.org/10.3390/diagnostics11030479

[10] L. Carvajal Barbosa, D. Insuasty Cepeda, A. F. León Torres, M. M. Arias Cortes, Z. J. Rivera Monroy, and J. E. Garcia Castaneda, "Nucleic acid-based biosensors: Analytical devices for prevention, diagnosis and treatment of diseases," *Vitae*, vol. 28, no. 3, p. 347259, 2021. https://doi.org/10.17533/udea.vitae.v28n3a347259

[11] T. Rendek *et al.*, "Current challenges of methylation-based liquid biopsies in cancer diagnostics," *Cancers*, vol. 16, no. 11, p. 2001, 2024. https://doi.org/10.3390/cancers16112001

[12] G. Huang, C. Su, L. Wang, Y. Fei, and J. Yang, "The application of nucleic acid probe–based fluorescent sensing and imaging in cancer diagnosis and therapy," *Frontiers in Chemistry*, vol. 9, p. 705458, 2021. https://doi.org/10.3389/fchem.2021.705458

[13] J. Yang, R. Xu, C. Wang, J. Qiu, B. Ren, and L. You, "Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review," *Cancer Communications*, vol. 41, no. 12, pp. 1257-1274, 2021. https://doi.org/10.1002/cac2.12204

[14] N. Mahdieh and B. Rabbani, "An overview of mutation detection methods in genetic disorders," *Iranian Journal of Pediatrics*, vol. 23, no. 4, p. 375, 2013.

[15] A. Wang *et al.*, "Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders," *Nature Cell Biology*, vol. 26, no. 2, pp. 219-234, 2024. https://doi.org/10.1038/s41556-023-01339-x

[16] L. M. Mollé, C. H. Smyth, D. Yuen, and A. P. Johnston, "Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery," *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, vol. 14, no. 6, p. e1809, 2022. https://doi.org/10.1002/wnan.1809

[17] A. Davydova, M. Vorobjeva, D. Pyshnyi, S. Altman, V. Vlassov, and A. Venyaminova, "Aptamers against pathogenic microorganisms," *Critical Reviews in Microbiology*, vol. 42, no. 6, pp. 847-865, 2016.

[18] E. M. Otiniano, "Comparing gene therapy with current standards of treatment," Doctoral Dissertation, 2019.

[19] L. A. Mott, "Towards the rational design and application of polymers for gene therapy: internalization and intracellular fate," *Polymers*, vol. 11, no. 4, p. 745, 2019.

[20] X. Shen and D. R. Corey, "Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs," *Nucleic Acids Research*, vol. 46, no. 4, pp. 1584-1600, 2018. https://doi.org/10.1093/nar/gkx1239

[21] M. Egli and M. Manoharan, "Chemistry, structure and function of approved oligonucleotide therapeutics," *Nucleic Acids Research*, vol. 51, no. 6, pp. 2529-2573, 2023. https://doi.org/10.1093/nar/gkad067

[22] A. Torres Vidal, I. L. Medintz, and H. Bui, "DNA microsystems for biodiagnosis," *Micromachines*, vol. 11, no. 4, p. 445, 2020. https://doi.org/10.3390/mi11040445

[23] D. S. Grewal, "Multidisciplinary approach in researching artificial intelligence, nanotechnology and biotechnology," *International Journal of Nanomaterials and Nanostructures*, vol. 10, no. 1, p. 8341, 2024.

[24] Y. Zhu *et al.*, "DNA nanotechnology in tumor liquid biopsy: Enrichment and determination of circulating biomarkers," *Interdisciplinary Medicine*, vol. 2, no. 1, p. e20230043, 2024. https://doi.org/10.1002/inmd.20230043

[25] W. H. Lewis, G. Tahon, P. Geesink, D. Z. Sousa, and T. J. Ettema, "Innovations to culturing the uncultured microbial majority," *Nature Reviews Microbiology*, vol. 19, no. 4, pp. 225-240, 2021.

[26] T. Ramasamy, S. Munusamy, H. B. Ruttala, and J. O. Kim, "Smart nanocarriers for the delivery of nucleic acid-based therapeutics: A comprehensive review," *Biotechnology Journal*, vol. 16, no. 2, p. 1900408, 2021.